• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    aTyr Pharma Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Other Events, Financial Statements and Exhibits

    5/29/24 4:03:07 PM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LIFE alert in real time by email
    8-K
    0001339970false00013399702024-05-222024-05-22

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 22, 2024

     

    ATYR PHARMA, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    001-37378

    20-3435077

    (State or other jurisdiction

    of incorporation)

    (Commission File Number)

    (IRS Employer

    Identification No.)

     

    10240 Sorrento Valley Road, Suite 300

    San Diego, CA

     

     

     

    92121

    (Address of principal executive offices)

     

     

    (Zip Code)

    Registrant’s telephone number, including area code: (858) 731-8389

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

    LIFE

    The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    (e) As reported in Item 5.07 below, at the 2024 Annual Meeting of Stockholders held on May 22, 2024 (the “Annual Meeting”) of aTyr Pharma, Inc. (the “Company”), the Company’s stockholders, upon the recommendation of the Company’s Board of Directors (the “Board”), approved an amendment to the Company’s 2015 Stock Option and Incentive Plan, as amended (the “2015 Stock Plan”), to increase the maximum number of shares of common stock reserved and available for issuance by 3,000,000 to 10,713,670. The amendment to the 2015 Stock Plan also, among other things, eliminates the term of the 2015 Stock Plan and extends the term under which incentive stock options may be granted until February 28, 2034.

    A summary of the 2015 Stock Plan, as amended, is set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 5, 2024 (the “Proxy Statement”). The summary and the foregoing description of the 2015 Stock Plan, as amended, do not purport to be complete and are qualified in their entirety by reference to the full text of the 2015 Stock Plan, as amended, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K.

     

    Item 5.05 Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics.

    On May 22, 2024, the Board adopted and approved certain amendments to the Company’s Code of Business Conduct and Ethics, as reflected in an amended version of the Code of Business Conduct and Ethics (the “Code”).

    The Code was amended to, among other things, augment and increase clarity and protections surrounding compliance with laws, rules and regulations and the culture of a respectful work environment free of unlawful discrimination and harassment. The description of the amendment to the Code contained in this Current Report on Form 8-K is qualified in its entirety by reference to the full text of the Code, as amended, filed as Exhibit 14.1 to this Current Report on Form 8-K. The Code, as amended, is also available on the Company’s website at https://atyrpharma.com under the corporate governance section.

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    The following proposals were submitted to the Company’s stockholders at the Annual Meeting:

    (1) The election of two Class III directors, as nominated by the Board, to hold office until the 2027 annual meeting of stockholders or until their successors are duly elected and qualified;

    (2) The ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024;

     

    (3) The approval, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement;

     

    (4) The approval of an amendment to the 2015 Stock Plan;

     

    (5) The approval of authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 4.

    The number of shares of common stock entitled to vote at the Annual Meeting was 67,940,841. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 54,876,228. All matters submitted to a vote of the Company’s stockholders at the Annual Meeting were approved and all director nominees were elected.

    The number of votes cast for and against and the number of votes withheld, abstentions and broker non-votes, as applicable, with respect to each matter voted upon at the Annual Meeting are set forth below. Voting results are, when applicable, reported by rounding fractional share voting down to the nearest round number.

     

     

    2


     

    Proposal 1 – Election of Class III Directors.

     

    Director Nominee

    Votes For

    Withhold

    Broker Non-Vote

    Svetlana Lucas, Ph.D.

    40,487,931

    2,429,225

    11,959,071

    Sanjay S. Shukla, M.D., M.S.

    42,624,285

    292,871

    11,959,071

     

     

     

     

     

    Proposal 2 – Ratification of the appointment of Ernst and Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024.

     

    Votes For

    Votes Against

    Abstain

    Broker Non-Vote

    54,516,489

    327,155

    32,584

    —

     

    Proposal 3 – Approval, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.

     

    Votes For

    Votes Against

    Abstain

    Broker Non-Vote

    42,468,397

    397,926

    50,833

    11,959,071

     

    Proposal 4 – Approval of an amendment to the 2015 Stock Plan.

     

    Votes For

    Votes Against

    Abstain

    Broker Non-Vote

    42,420,639

    438,006

    58,511

    11,959,071

     

    Proposal 5 – Approval of authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 4.

     

    Votes For

    Votes Against

    Abstain

    Broker Non-Vote

    42,342,487

    551,437

    23,232

    11,959,071

     

    Item 8.01 Other Events.

    In September 2022, the Company dosed the first patient in its global pivotal Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis (the “EFZO-FIT study”). The EFZO-FIT study is currently enrolling and intends to enroll up to 264 subjects with pulmonary sarcoidosis at multiple centers in the United States, Europe, Brazil, and Japan. The Company anticipates completing enrollment of the EFZO-FIT study in the second quarter of 2024, but final screenings of potential patients may lead to dosing of the final patient in July 2024.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit No.

    Description

    10.1

     

    aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan, as amended

    14.1

     

    aTyr Pharma, Inc. Code of Business Conduct and Ethics, as amended

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     Indicates a management contract or compensatory plan, contract or arrangement.

     

     

    3


     

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ATYR PHARMA, INC.

    By:

    /s/ Jill M. Broadfoot

    Jill M. Broadfoot

    Chief Financial Officer

     

    Date: May 29, 2024

     

     

    4


    Get the next $LIFE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LIFE

    DatePrice TargetRatingAnalyst
    7/5/2023Outperform → Perform
    Oppenheimer
    11/11/2021$18.00 → $11.00Buy
    HC Wainwright & Co.
    11/11/2021$18.00 → $11.00Action List Buy
    HC Wainwright & Co.
    10/12/2021$22.00Outperform
    RBC Capital
    9/21/2021$19.00Overweight
    Piper Sandler
    9/14/2021$20.00 → $21.00Buy
    Roth Capital
    9/14/2021$14.00 → $20.00Outperform
    Oppenheimer
    9/13/2021$13.00 → $18.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LIFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Denyes Nancy bought $9,276 worth of shares (5,000 units at $1.86), increasing direct ownership by 29% to 22,267 units (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/6/24 8:26:55 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coughlin Timothy bought $87,500 worth of shares (50,000 units at $1.75) (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/3/24 4:21:12 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Broadfoot Jill Marie bought $8,950 worth of shares (5,000 units at $1.79), increasing direct ownership by 22% to 27,960 units (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/3/24 8:38:39 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from "LIFE" to "ATYR"

      SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will be changing its ticker symbol from "LIFE" to "ATYR." Effective at the market open on June 5, 2024, the Company's common stock will trade on the Nasdaq Capital Market under the new symbol "ATYR." "As we advance our lead therapeutic candidate, efzofitimod, through a pivotal Phase 3 study in pulmonary sarcoidosis and prepare for potential commercialization, the "ATYR" ticker symbol is a strong reflec

      6/3/24 8:00:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, May 24, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 9,400 shares of aTyr's common stock, each with an exercise price of $1.86 per share, which is equal to the closing price of aTyr's common stock on the Nasdaq Capital Market on May 22, 2024, the effective date of the grants. These stock awards were granted as an inducement material

      5/24/24 4:00:00 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

      SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2024 International Conference, which is scheduled to take place May 17 – 22 in San Diego, CA. "These findings further demonstrate the unique way in which efzofitimod is modulating myeloid cells to confer the anti-inflammatory benefits we have seen in patients with pulmonary sarcoidosis, a major form o

      5/15/24 7:00:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    Financials

    Live finance-specific insights

    See more
    • aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

      Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged

      3/14/24 4:00:00 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

      SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 14, 2024Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI834bef07b22642ae8be51b7

      2/28/24 8:00:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results

      SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate update after the market close on Thursday, March 9, 2023. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 9, 2023Time: 5:00 p.m. EST / 2:00 p.m. PSTDial-In Registration: https://register.vevent.com/register/BI01f8362bebee42539116051

      3/2/23 8:00:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

      SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

      2/14/24 1:43:55 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

      SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

      2/13/24 4:30:17 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

      SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

      2/9/24 8:35:54 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Denyes Nancy bought $9,276 worth of shares (5,000 units at $1.86), increasing direct ownership by 29% to 22,267 units (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/6/24 8:26:55 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coughlin Timothy bought $87,500 worth of shares (50,000 units at $1.75) (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/3/24 4:21:12 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Broadfoot Jill Marie bought $8,950 worth of shares (5,000 units at $1.79), increasing direct ownership by 22% to 27,960 units (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/3/24 8:38:39 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    SEC Filings

    See more
    • aTyr Pharma Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Other Events, Financial Statements and Exhibits

      8-K - aTYR PHARMA INC (0001339970) (Filer)

      5/29/24 4:03:07 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by aTyr Pharma Inc.

      10-Q - aTYR PHARMA INC (0001339970) (Filer)

      5/2/24 4:07:23 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - aTYR PHARMA INC (0001339970) (Filer)

      5/2/24 4:04:01 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • aTyr Pharma downgraded by Oppenheimer

      Oppenheimer downgraded aTyr Pharma from Outperform to Perform

      7/5/23 7:41:57 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on aTyr Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of aTyr Pharma with a rating of Buy and set a new price target of $11.00 from $18.00 previously

      11/11/21 6:10:41 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on aTyr Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of aTyr Pharma with a rating of Action List Buy and set a new price target of $11.00 from $18.00 previously

      11/11/21 6:10:41 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    Leadership Updates

    Live Leadership Updates

    See more
    • aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

      SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Wayne A. I. Frederick, M.D., as an advisor to the company. Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023. "We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Dr. Frederick's clinical background combined with

      1/18/24 8:00:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources

      SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Danielle Campbell to Vice President, Human Resources. Ms. Campbell will serve as a member of the company's executive leadership team and oversee all aspects of human resources strategies and functions, including organizational development, talent management and talent acquisition initiatives. "We are delighted to welcome Danielle to aTyr at a pivotal time in the company's journey as we expand our team to support our next phase of growth," said Sanjay S.

      12/24/21 8:02:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

      NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ

      11/2/21 9:00:00 AM ET
      $AMGN
      $APVO
      $BCTX
      $BMY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations